MedTrace Logo

Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair

NCT02084069 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2015-03-04

Study results available
· View outcomes & findings →

Summary

The purpose of the investigation is to determine whether Atrovastatin as anti-inflammatory agent can be effective in preventing from atrial fibrillation incidence in patients whom undergone open cardiac surgery for their heart valve repair.

Conditions

  • Heart Valve Diseases

Interventions

DRUG

Atorvastatin

Sponsors & Collaborators

  • Urmia University of Medical Sciences

    lead OTHER

Principal Investigators

  • Yousef Rezaei, M.D · Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02084069 on ClinicalTrials.gov